Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 5/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.33 |
| ▸ | VEGFA | P15692 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964210 | 0.85 | AKR1B1 (0.34) | THRBALDH1A1LMNAAKR1B1 | |
| SCHEMBL5004858 | 0.84 | AKR1B1 (0.33) | KMT2AAKR1B1 | |
| SCHEMBL5963749 | 0.83 | FPR2 (0.34) | ALDH1A1LMNAAKR1B1 | |
| SCHEMBL5963305 | 0.82 | SLC6A3 (0.39) | THRBALDH1A1LMNAAKR1B1 | |
| SCHEMBL5007459 | 0.82 | FPR2 (0.32) | AKR1B1 | |
| SCHEMBL5963456 | 0.81 | SLC6A2 (0.36) | KMT2A | |
| SCHEMBL5963556 | 0.80 | KMT2A (0.34) | KMT2ALMNA | |
| SCHEMBL5963589 | 0.78 | SLC6A4 (0.38) | ALDH1A1LMNAAKR1B1 | |
| SCHEMBL5963772 | 0.78 | AKR1B1 (0.33) | ALDH1A1LMNAAKR1B1 | |
| SCHEMBL6820213 | 0.78 | AKR1B1 (0.39) | KMT2ATHRBALDH1A1LMNAAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125840-B2 | Substituted dipeptides as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1326851-B1 | SUBSTITUTED DIPEPTIDES AS GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040058971-A1 | Substituted dipeptides as growth hormone secretagogues | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058971-A1 | Substituted dipeptides as growth hormone secretagogues | GHSR, GHRHR, SSTR4 | KMT2A 3557/4885THRB 155/4885TP53 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.